Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical Co Ltd Chief Transformation Officer Lauren Rusckowski Duprey received an equity award tied to performance goals. On April 27, 2026, she was granted 59,990 American Depositary Shares at a price of $0.00 per share as a grant or award acquisition.
After this award, she directly holds 228,503 American Depositary Shares, including 146,762 restricted stock units that may convert into shares. These RSUs vest on a schedule: 100,658 shares on July 1, 2026, 30,488 shares on July 1, 2027, and 15,616 shares on July 1, 2028, contingent on prior performance metrics such as core revenue, core operating profit, and important R&D milestones.
Kim Julie So-Young reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that CEO-elect Julie So-Young Kim received a grant of 105,416 American Depositary Shares (ADS) on April 27, 2026, following performance-based RSU metrics set from a July 1, 2023 award. After this grant, she holds 430,145 ADS, including 256,372 RSUs that vest in stages from July 1, 2026 through July 1, 2028.
Platford Giles Richard reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Giles Richard Platford, President IBU, received a grant of 72,124 American Depositary Shares on April 27, 2026 as a performance-based restricted stock unit (RSU) award at no cash cost to him.
The award was determined by the Compensation Committee using performance metrics including core revenue, core operating profit and important R&D milestones from an RSU grant originally made on July 1, 2023. Following this award, Platford directly holds 297,363 American Depositary Shares, including 166,744 RSUs scheduled to vest on July 1, 2026 (116,762 shares), July 1, 2027 (32,396 shares) and July 1, 2028 (17,586 shares).
Pignagnoli Agosti Marcello reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Marcello Pignagnoli Agosti received an award of 27,740 American Depositary Shares on April 27, 2026. The grant reflects performance-based restricted stock units tied to core revenue, core operating profit, and key R&D milestones.
After this award, he directly holds 172,348 American Depositary Shares, including 81,590 restricted stock units. These RSUs are scheduled to vest in tranches on July 1, 2026 (52,250 shares), July 1, 2027 (19,798 shares), and July 1, 2028 (9,542 shares).
Takeda Pharmaceutical (TAK) executive Nicola Deidre Petal Greenway, Chief Human Resources Officer, reported initial beneficial ownership of 71,836 American Depositary Shares.
This total includes 37,458 restricted stock units (RSUs), which are scheduled to vest in tranches on July 1, 2026, July 1, 2027, and July 1, 2028.
Takeda Pharmaceutical’s Chief Medical Officer, Farajallah Awny Samaan Botros, reported his initial shareholdings in the company. He holds 112,629 American Depositary Shares directly, including 73,220 restricted stock units that convert into ADSs as they vest on scheduled dates from July 1, 2026 through July 1, 2028.
Takeda Pharmaceutical executive Ibrahim Ramy Riad Ahmed filed an initial statement of ownership, reporting 84,787 American Depositary Shares of the company. This total includes 48,928 restricted stock units (RSUs), each convertible into one ADS. The RSUs vest in stages on July 1, 2026 (24,022 shares), July 1, 2027 (16,554 shares) and July 1, 2028 (8,352 shares), showing a multi‑year equity-based compensation structure tied to his role as President of the PDT business unit.
Takeda reported strong Phase 3 results for its investigational oral TYK2 inhibitor zasocitinib (TAK-279) in adults with moderate‑to‑severe plaque psoriasis. In two large global LATITUDE PsO studies, about 70% of patients on zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16, far exceeding placebo and apremilast.
Zasocitinib also drove high rates of deeper responses: over half of treated patients reached PASI 90 at week 16, and roughly one‑third achieved complete skin clearance (PASI 100 and sPGA 0), with responses improving through week 24. More than 90% of responders who stayed on drug at week 40 maintained sPGA 0/1, PASI 75 and PASI 90 through week 60, indicating durable control.
The once‑daily pill showed a safety profile consistent with earlier trials, with treatment‑emergent adverse events in 62.1% of zasocitinib patients versus 46.9% on placebo and 50.5% on apremilast; the most common were upper respiratory infection, nasopharyngitis and acne, and no new safety signals were seen. Takeda plans to begin New Drug Application filings in fiscal 2026, targets a first psoriasis launch in the first half of 2027, and cites combined psoriasis and psoriatic arthritis peak revenue potential of $3‑6B, though these results do not change its full‑year forecast to March 31, 2026.
Takeda Pharmaceutical Company Limited is advancing its leadership transition and Board renewal. The Board will propose CEO-elect Julie Kim as a new internal director at the 150th Ordinary General Meeting of Shareholders on June 24, 2026. If elected, she will be appointed representative director, president & CEO immediately after the meeting, while current representative director, president & CEO Christophe Weber plans to retire from Takeda and its Board on the same day.
Takeda is also reshaping its Board with three new external candidates – Bruce Broussard, Koichiro Kimura and Paul Stoffels – and the planned retirement of six current external directors. All other current Board members are expected to be proposed for re-election. An attachment notes that Julie Kim holds 173,773 ADSs and outlines her prior leadership roles at Shire and Takeda, reinforcing her experience ahead of assuming the top role.
Takeda Pharmaceutical Company Limited is launching the next phase of its global transformation program to boost competitiveness and support multiple upcoming drug launches. The company targets annualized gross savings of more than JPY 200 billion by FY2028, mainly through streamlined corporate functions, simpler processes and better use of technology.
These efficiencies are expected to largely offset investments in launch preparations for medicines such as oveporexton, rusfertide and zasocitinib, as well as late-stage pipeline and technology spending. Takeda currently estimates restructuring expenses of about JPY 150 billion in FY2026, with smaller charges in FY2027 and FY2028. The initiatives are not expected to have a significant impact on the full-year consolidated financial forecast for FY2025.